Content Type: Research Publications

Whistle-Blowers’ Experiences in Fraud Litigation Against Pharmaceutical Companies

March 15, 2026

State Generic Substitution Laws Can Lower Drug Outlays Under Medicaid

March 15, 2026

Fighting Antibiotic Resistance: Marrying New Financial Incentives to Meeting Public Health Goals

March 15, 2026

Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation

March 15, 2026

A Comparative Analysis of International Drug Price Negotiation Frameworks: an Interview Study of Key Stakeholders

March 6, 2026

Constructing Opioid Legitimacy: The Canadian Pain Task Force’s Framing of the Overdose Crisis

March 6, 2026

Discovering a Transformative Cancer Drug: The Case of Ibrutinib

March 6, 2026

Estimating Racial and Ethnic Disparities in Substance Use Disorder Treatment and Harm Reduction Services: Findings From a Survey of People Who Use Drugs

March 6, 2026

Characteristics of Speakers at US FDA Advisory Committee Meetings on Drug Approval

March 6, 2026

Stigma, Scarcity and the Price of Legitimacy: Chronic Pain Advocacy and the Politics of Pharmaceutical Partnerships in Canada

March 6, 2026

Tertiary Patents on Drugs Approved By the FDA

March 6, 2026

Changes in Medication Use During Medicaid Continuous Enrollment and Unwinding

March 6, 2026